Introduction
Integrin-linked kinase (ILK) was originally described as a serine/threonine protein kinase binding directly to, and transducing signals from, b1 integrin subunits (Hannigan et al., 1996) . ILK is comprised of three evolutionarily conserved domains: an N-terminal ankyrin repeat domain, a central pleckstrin-homology (PH)-like domain and a C-terminal catalytic domain (McDonald et al., 2008a) . Genetic studies in Drosophila, Caenorhabditis elegans, Xenopus laevis, zebrafish and mice have shown a requirement for ILK in embryonic development. These studies have shown a key functional linkage of ILK to integrins, coupling extracellular signals to regulation of the actin cytoskeleton and intracellular signaling cascades regulating cell growth, survival and migration (McDonald et al., 2008a) . ILK localizes to focal adhesions and myofilaments, and more recently it was discovered to interact with tubulin and tubulin-associated proteins , to regulate the trafficking of caveolae (Wickstrom et al., 2010a) , and to localize to centrosomes where it assembles distinct, tubulin-based multi-protein complexes and regulates mitotic spindle assembly through interactions with chTOG, TACC3 and Aurora-A kinase . In addition, many studies have shown elevated ILK protein levels and activity in a variety of cancers (McDonald et al., 2008a; Cabodi et al., 2010) , indicating its potential as a target for new cancer treatments (Hannigan et al., 2005) .
Over the past several years there has been an ongoing debate about whether ILK is a bona fide protein kinase or a pseudokinase (Hannigan et al., 2005; Boudeau et al., 2006; McDonald et al., 2008a; Wickstrom et al., 2010b) . Thus, while we strive to gain an understanding of the basic biology of ILK, it is important to resolve the issue of whether it is a bona fide or pseudokinase, particularly in the context of the development of therapeutic agents targeting aberrant ILK signaling. Furthermore, the unusual kinase domain provides an important opportunity to gain insight into a potentially unusual, even unique, catalytic mechanism, which again could be of great therapeutic benefit.
Our objectives here are to identify and evaluate the evidence that favors ILK as (i) a bona fide protein kinase with additional scaffolding functions, or (ii) a pseudokinase whose functions are exclusively mediated by protein-protein interactions, and to suggest additional evidence that could help resolve the issue. Our approach will be to define a set of criteria that need to be met to establish that a putative protein kinase shows catalytic activity that has a physiological role in cell signaling, and, for each criterion, to critically evaluate the evidence for and against. Table 1 summarizes the evidence that will be discussed in detail.
Does ILK fulfill the biochemical and biological criteria shown by protein kinases?
The protein contains a kinase catalytic domain in which key residues, shown to be important for activity in other kinases, are conserved These features are described in detail in references Hanks et al. (1988) and Hanks and Hunter (1995) . It was an analysis of the sequence of the ILK catalytic domain that originally led to the suggestion that it may be a pseudokinase (Balendran et al., 1999; Lynch et al., 1999) , as it lacks the highly conserved DFG and HRD motifs, although it does retain the ATP-binding Lys residue (K220) and the invariant APE motif. However, based on other kinases, which differ from the classical catalytic domain sequences, there is more sequence flexibility within a kinase catalytic domain than was originally thought. For example, the Walker A-motif (GXGXXG) in sub-domain-I of most protein kinases, which covers the a and b-phosphates of ATP, is NENHSG in human ILK, but other kinases, such as Mik1 and Vps15p, also lack all three Gly residues (Herman et al., 1991; Lundgren et al., 1991) . In addition, CASK and haspin both lack the DFG motif (haspin also lacks the APE motif), but both are catalytically functional (Mukherjee et al., 2008; Eswaran et al., 2009 ). An examination of the amino-acid sequence of the catalytic domain, therefore, is not sufficient to conclude that ILK is a pseudokinase.
The pure enzyme shows kinase activity in vitro using a peptide or protein substrate Numerous studies have concluded that ILK can directly phosphorylate several peptides and proteins in vitro (Hannigan et al., 2005; McDonald et al., 2008a) . These include b1-integrin (Hannigan et al., 1996) , myelin basic protein (Hannigan et al., 1996) ; b-parvin (Yamaji et al., 2001) ; glycogen synthase kinase-3b (GSK-3b) (Delcommenne et al., 1998) ; Akt (Persad et al., 2001) ; the regulatory light chain of myosin-II, MLC-20 ; the protein phosphatase-inhibitory proteins CPI-17, PHI-1 and KEPI (Erd + odi et al., 2003) ; the myosin-targeting subunit of the myosin (Attwell et al., 2003) Lactation, mammary differentiation (Akhtar et al., 2009 ) Smooth-muscle contraction; MLC-20 phosphorylation Eto, 2009) Mitotic spindle organization (Fielding et al., , 2011 ) Renal agenesis (Lange et al., 2009 ) Akt Ser473 phosphorylation, cell survival (Persad et al., 2000 (Persad et al., , 2001 ) Zebrafish muscle fiber-ECM adhesion (Postel et al., 2008) Human cardiomyopathy (Knoll et al., 2007) (Zervas et al., 2001) Inhibition of growth, and apoptosis of anaplastic thyroid cancer cells (Younes et al., 2005) Pancreatic cancer xenograft apoptosis (Yau et al., 2005 ) Mammary tumor growth (White et al., 2001) Abbreviation: ILK, integrin-linked kinase. Evidence for kinase dependence is based on effects of point mutations predicted or shown to affect catalytic function, or inhibition by the QLT class of inhibitor, with or without corroborating genetic knockout/knockdown data. Scaffold/uncertain designation is based on loss of a known protein interaction, lack of inhibitory effect of ILK mutants on signaling, genetic rescue by kinase mutant or ILK knockout/knockdown, without smallmolecule inhibitor data.
light chain phosphatase, MYPT1 (Mura´nyi et al., 2002) and a-NAC (Quelo et al., 2004) . Following the initial discovery of ILK and in vitro characterization of its kinase activity (Hannigan et al., 1996) , a research question related to the mechanism of activation of smooth-muscle contraction provided independent support for the conclusion that ILK is a bona fide protein serine/threonine kinase. It had been known for many years that a variety of contractile stimuli act through increase in cytosolic free Ca 2 þ concentration ([Ca 2 þ ] i ), which results in binding of Ca 2 þ to calmodulin and activation of myosin light-chain kinase, which phosphorylates the regulatory light-chain subunits (MLC-20) of smooth-muscle myosin-II (specifically at Ser-19) to activate cross-bridge cycling and contraction (Allen and Walsh, 1994) . Several investigators had observed that phosphatase inhibitors could induce smooth-muscle contraction in a Ca 2 þ -independent manner. For example, treatment of Triton-skinned (de-membranated) vascular smooth muscle strips with microcystin-LR (a type-1 and 2A protein serine/ threonine phosphatase inhibitor) elicited a Ca 2 þ -independent contraction, which correlated with MLC-20 phosphorylation (Weber et al., 1999) . Several lines of compelling evidence indicated that the kinase responsible for this Ca 2 þ -independent phosphorylation of MLC-20 and contraction was not myosin light-chain kinase (Weber et al., 1999; Wilson et al., 2005) . The kinase was partially purified from chicken gizzard smooth-muscle myofilaments, using the phosphorylation of purified MLC-20 and intact myosin-II at Ser-19 and Thr-18 of the light chain in the absence of Ca 2 þ as the assay to monitor purification. In-gel kinase assays in which MLC-20 was incorporated throughout the gel, and activity assayed in the absence of Ca 2 þ , identified a 59-kDa protein as the putative Ca 2 þ -independent MLC-20 kinase . The same column fractions showed in-gel kinase activity using Akt as substrate, phosphorylation occurring on Ser-473 (Persad et al., 2001) . Importantly, we eliminated the possibility that the Ca 2 þ -independent MLC-20 kinase activity may have been because of constitutively active myosin light-chain kinase, lacking the autoinhibitory and calmodulinbinding domains, which could be generated by partial proteolysis . Using kinase inhibitors (HA-1077 and AV25, respectively), we also ruled out contamination by Rho-associated kinase and zipperinteracting protein kinase Wilson et al., 2005) , both of which can phosphorylate MLC-20 at Ser-19 and Thr-18 in vitro (Amano et al., 1996; Murata-Hori et al., 1999; Niiro and Ikebe, 2001) . Mass spectrometry of the 59-kDa protein band excised from the gel identified it as ILK, and no contaminating kinases or other proteins were detected in the mass spectrometric analysis . The possibility of trace contamination with a distinct kinase of very high specific activity, however, cannot be completely ruled out. However, western blotting of column fractions using anti-ILK indicated that the intensity of ILK staining correlated with the in-gel kinase assay of the Ca 2 þ -independent activity of MLC-20 kinase. ILK was cloned from chicken gizzard smooth muscle, expressed in Escherichia coli as a glutathione S-transferase (GST)-fusion protein and purified to electrophoretic homogeneity by glutathione-Sepharose and ion-exchange chromatography. The GST moiety was cleaved off and the kinase was purified on a glutathione-Sepharose column. The purified recombinant ILK, which is 90.7% identical in sequence to human ILK , was shown to phosphorylate MLC-20 in purified, intact smooth-muscle myosin-II in the absence of Ca 2 þ . Approximately 73% of total ILK (from in-gel kinase activity measurements) was recovered in the Tritoninsoluble fraction of chicken gizzard smooth muscle, the remainder presumably corresponding to integrin-associated ILK .
Subsequently, by using solution and in-gel kinase assays, ILK was shown to directly phosphorylate MYPT1 (the myosin-targeting subunit of myosin lightchain phosphatase) (Mura´nyi et al., 2002) (Figure 1 ) and members of the CPI-17 family of protein phosphatase inhibitors Eto, 2009) (Figure 2 ), which had previously been shown to be phosphorylated at the same sites (Thr-38 of CPI-17, Thr-73 of KEPI and Thr-57 of PHI-1) by protein kinase-C (Eto, 2009) . These phosphorylations convert the proteins from inactive to active phosphatase inhibitors. It was concluded from these observations that ILK induces Ca 2 þ -independent, myosin phosphorylation-mediated smooth-muscle contraction directly through phosphorylation of MLC-20, and indirectly through phosphorylation and activation of myosin light-chain phosphatase (PP1)-inhibitory proteins ( Figure 2 ).
To address the question of ILK's kinase activity more thoroughly, we showed that the highly purified recombinant ILK protein shows robust kinase activity in vitro, phosphorylating MLC-20 and the crosstide peptide substrate encompassing Ser-9 of GSK-3b with a K m of 2-3 mM for MnATP (Maydan et al., 2010 ). An in-depth Michaelis-Menten analysis of catalytic activity showed that the enzyme kinetic properties of ILK are very similar to those of other active protein kinases, with the unusual property of being much more active with MnATP rather than MgATP as substrate. Mutant ILK (K220A), in which the ATP-binding Lys-220 was mutated to Ala, showed greatly reduced phosphotransferase activity toward these substrates in vitro (Maydan et al., 2010) . Recombinant, full-length GST-ILK and GST-ILK K220M used in these assays were 494% pure, and mass spectrometric analysis failed to detect any contaminating kinases in either preparation.
Numerous studies have reported kinase activity associated with ILK in immunoprecipitation and pulldown assays (reviewed by McDonald et al. (2008a) ). More recently, in a study investigating the mechanism whereby transgenic expression of a7-integrin in a mouse model of Duchenne muscular dystrophy ameliorates muscle pathology (Boppart et al., 2011) , ILK kinase activity and ILK protein levels were comparably elevated, and correlated with an increase in phosphatidylinositol-3-kinase (PI3K) activity, Akt phosphorylation and p70S6K activity, consistent with activation of ILK by phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ) and sequential phosphorylation of Akt and p70S6K.
Collectively, these in vitro studies strongly implicate a kinase function for ILK, although it remains to be determined whether this activity is manifest in vivo. The chemical genetic approach pioneered by Shokat and coworkers (Knight and Shokat, 2007) could prove useful in this regard, but additional knowledge of the threedimensional (3D) structure of the active kinase will be required to engineer mutants in which the gate-keeping residues marking entry into the ATP-binding site can be identified.
The 3D structure of the full-length enzyme shows the kinase catalytic mechanism The high-resolution structure of the catalytic domain of ILK fused to the C-terminal CH domain of a-parvin has been reported, and it was concluded that the conformation was incompatible with catalytic activity (Fukuda et al., 2009) . The authors extrapolated from here to the conclusion that ILK must be a pseudokinase. However, it is likely that the presence of the a-parvin CH domain maintains the kinase domain in an inactive conformation. Indeed, binding of a-parvin to full-length ILK markedly decreased kinase activity using GSK-3b peptide as substrate (Maydan et al., 2010) . It will be necessary to elucidate the structure of the full-length, wild-type ILK in order to determine the catalytic mechanism, which is clearly not the same as that of conventional protein kinases.
The activity of the enzyme is regulated by, for example, phosphorylation by an upstream kinase, protein-protein interactions or binding of an allosteric regulator ILK appears to be capable of autophosphorylation (Hannigan et al., 1996) , but the effect on activity is unknown. Ser-343 in the activation loop of ILK is implicated as a possible site of activating phosphorylation as a phosphomimetic substitution, S343D, results in constitutively active ILK and enhanced signaling in cell culture (Persad et al., 2001) . Conversely, S343A is a putative non-phosphorylatable ILK variant that acts as a dominant negative to suppress ILK signaling (Persad et al., 2001) . However, mice carrying a genetically knocked-in S343A-or S343D-mutant ILK develop normally (Lange et al., 2009) , suggesting (i) that the catalytic activity of ILK does not have a role in mammalian development or (ii) a redundancy in critical kinase-dependent developmental functions of ILK.
ILK has been shown to be phosphorylated at two other sites, Thr-173 and Ser-246, and the upstream kinase appears to be the p21-activated protein kinase, PAK1 (Acconcia et al., 2007) . Nothing is known regarding the effects of these phosphorylations on ILK activity, but phosphorylation at T173 has been correlated with increased ILK signaling (Suh and Han, 2011) . Further studies will be necessary to establish the regulatory significance of these phosphorylation sites.
The kinase domain of ILK can interact with several adaptor proteins, in addition to b-integrins. These include a-, b-and g-parvins, which interact with ILK through their second CH domain (Wickstrom et al., 2010b) , and the focal adhesion proteins paxillin Turner, 2001, 2002) and parvins (Legate et al., 2006) . Our recent observation that ILK is inhibited by a-parvin (Maydan et al., 2010) supports the hypothesis that ILK activity may be regulated in vivo by protein-protein interactions, but this requires further study.
Disruption of ILK/a-parvin interaction in ILK K220M-mutant mice was cited as evidence that K220 identifies the parvin-binding site, rather than an ATPbinding residue. However, the structure of the kinasedead enzyme (ILK KD) bound to the CH domain of aparvin (Fukuda et al., 2009) confirms that K220 is an ATP-coordinating residue. Conversely, residues M402 and K403 in the G-helix of the kinase domain provide extensive contacts with the CH domain of a-parvin, and are spatially distant from K220 in the P-loop of ILK (Figure 3 ). An M402A/K403A double-mutant ILK protein does not bind a-parvin or localize to focal adhesions, whereas K220M shows normal localization (Fukuda et al., 2009) , indicating distinct functional significance of the ATP-and parvin-binding sites of the ILK kinase domain. It is thus probable that a-parvin binding is dependent on the kinase activity of ILK, providing one example of interdependence between the signaling and scaffolding functions of ILK. Thus, the elegant knock-in study by Lange et al. (2009) actually provides evidence for both kinase-dependent and -independent functions of ILK in mammalian development.
The ankyrin repeat domain of ILK also mediates important protein-protein interactions: PINCH-1 and -2, which contain five LIM domains, bind to ILK through the first of these LIM domains (Chiswell et al., 2008) , and this domain of ILK also binds to the ILK-associated protein, ILKAP, which is a type-2C protein phosphatase that negatively regulates ILK signaling (Leung-Hagesteijn et al., 2001; Kumar et al., 2004) .
ILK activity appears to be activated by PIP 3 , a product of PI3K (Delcommenne et al., 1998) , consistent with the presence of a PH-like (PIP 3 -binding) domain within the ILK sequence (Hannigan et al., 1996) . The binding of PIP 3 to this domain of ILK has been verified by Pasquali et al. (2007) . However, this activation may be context-specific. We did not observe an increase in the ILK-mediated phosphorylation of MLC-20 by PIP 3 , but studies involving Gi-coupled receptor activation in smooth muscle have shown ILKmediated phosphorylation of MLC-20 to be PI3K-dependent (Huang et al., 2006 ). An R211A mutation in the PH-like domain of ILK generates a variant that is not activated by phosphoinositides (Persad et al., 2001; Attwell et al., 2003) , although the catalytic domain of ILK remains intact. This may explain why R211A-knock-in mice develop normally, and further suggests non-PI3K-mediated activation of ILK signaling during embryogenesis. In contrast to these kinase mutants, knock-in of the ILK K220M ATP-binding mutant does cause developmental abnormalities in mice, with early postnatal death from severe renal agenesis (Lange et al., 2009 ).
Mutagenesis of key residues known to be required for catalytic activity, for example, a critical ATP-binding Lys, results in loss of kinase activity Several site-specific mutations in ILK have been associated with loss of catalytic activity, including mutation of the putative phosphorylation site (S343A), the PIP 3 -binding site within the PH-like domain (R211A) or the ATP-binding Lys (K220A and K220M) (Persad et al., 2001; Filipenko et al., 2005) . The K220 mutations result in marked inhibition of ILK's kinase activity (Maydan et al., 2010) , and, in contrast to wild-type ILK, the K220A and K220M mutants fail to rescue GSK-3b phosphorylation, LEF-1 expression and somite development inhibited by knock- Figure 3 The ILK catalytic domain: A model. (a) A theoretical model of the ILK catalytic domain generated using the MacPY-MOL software, using the representative serine/threonine protein kinase domain of PKA as template. The model is in overall agreement with the global structure of ILK KD (Fukuda et al., 2009) , and illustrates the major structural features of the canonical kinase fold of ILK. The N-terminal lobe folds into a five-stranded antiparallel b-sheet and the C-terminal lobe consists of a bundle of a-helices and two short antiparallel b-strands (Fukuda et al., 2009) . In particular, the M402 and K403 residues are located in the Ghelix of the C-lobe, distant from K220, which bridges the a and g phosphates of ATP, located in the fold between the N-and C-lobes (Fukuda et al., 2009) . This structure illustrates the spatial separation of K220 from the G-helix residues, M402/K403, that mediate parvin binding. down of b1-integrin in vivo . Although studies have suggested some developmental functions may not involve the kinase function of ILK, recent evidence indicates that ILK kinase activity may be critical during vertebrate segmentation, highlighting potential tissue-restricted developmental roles for kinase activity. During vertebrate embryogenesis, bilateral pairs of somites bud off from the unsegmented presomitic mesoderm lying on either side of the neural tube, giving rise to vertebrae, skeletal muscles and some dermal structures. Somitogenesis depends on signaling by multiple pathways, including b1-integrin and Wnt . ILK is required for b1-integrin-dependent Wnt signaling and somite formation in the chick embryo presomitic mesoderm, and genetic rescue experiments further support a requirement for its kinase activity in this process. Unlike wild-type or constitutively active S343D ILK (see below), the ILK mutants K220M, E359K and S343A do not rescue somite formation or Wnt signaling in the presomitic mesoderm . Specifically, integrin ligation induces GSK-3b Ser-9 phosphorylation, which is completely abolished by the kinase-defective ILK K220A and K220M mutants . This elegant work provides strong supportive evidence for an indispensable role for kinase activity during somitogenesis. The possibility that such loss-of-function mutations exert their effects by disrupting protein-protein interactions rather than abrogating catalytic activity, however, cannot be completely ruled out. For example, the R211A mutation disrupts the interaction of ILK with a-parvin and interferes with the recruitment of ILK to focal adhesions (Attwell et al., 2003) , and the K220A mutation reduces the binding of b-parvin (Yamaji et al., 2001 ).
Conversely, mutation of an activation loop serine residue to a phosphomimetic (glutamate or aspartate) results in the activation of kinase activity This has been shown for S343 of ILK, which resides in the putative activation loop within the kinase domain (Persad et al., 2001) . The S343D mutant rescues the serum-depleted inhibition of Akt Ser-473 phosphorylation, and also rescues GSK-3b Ser-9 phosphorylation and somite development owing to b1-integrin inactivation in vivo. By contrast, the S343A (non-phosphorylatable) mutant fails to rescue these phenotypes. As described earlier, an important caveat to these studies is that such mutations could also affect protein-protein interactions. Interestingly, the S343D/K220M double mutation reversed the kinase-dead phenotype, but lost the ability to bind to ATP (Lynch et al., 1999) .
Targeted expression of the kinase has a characteristic phenotype consistent with kinase activity Genetic experiments have provided evidence supporting the role of ILK kinase activity in cardiac growth, as well as its importance for maintaining the structural integrity of the vertebrate heart (Hannigan et al., 2007) . Cardiacspecific expression of ILK in mice promotes physiologic hypertrophy, indicating a critical role for ILK-dependent signaling during cardiac cell growth. ILK induces the phosphorylation and activation of growth-regulatory signaling cascades, principally involving extracellular signal-regulated kinases (ERKs) and p70S6K (Hannigan et al., 2007) . Importantly, unlike wild-type ILK, the non-activatable R211A mutant does not induce these phosphorylations, suggesting a requirement for ILK kinase activity and signaling downstream from PI3K in regulating the growth of the mammalian heart. In addition to growth regulation, ILK is essential for maintenance of cardiac structural integrity, and genetic experiments moreover point to its kinase activity in mediating this effect. ILK localizes in, and contributes to, the sarcomeric structure and function in the vertebrate heart (Bendig et al., 2006) . In mice, cardiac ablation of ILK causes a severe pathologic hypertrophy, with massive disruption of sarcomeric organization, rapid onset of dilated cardiomyopathy and death (White et al., 2006) . The zebrafish cardiac contractility mutant, msq, is caused by a point mutation (L208P) in the catalytic domain of ILK, which reduces in vitro kinase activity and disrupts sarcomeric binding to b-parvin (Bendig et al., 2006) . In zebrafish the lost-contact (loc) mutant lacks functional ILK, causing mechanical instability in skeletal muscle fibers and severe muscular dystrophy (Postel et al., 2008) . Importantly, the ATPbinding ILK mutants, K220M and K220A, do not rescue loc-mutant animals, suggesting a requirement for ILK kinase activity in mediating the adhesion of muscle fibers to the extracellular matrix (Postel et al., 2008) . Interestingly, in all of these cases ILK deletion or mutation results in decreased phosphorylation of Akt on Ser-473, further implicating ILK kinase function. Mutations residing in the ILK kinase domain are also found in patients with dilated cardiomyopathy (Knoll et al., 2007) . Thus, evidence supports important roles for both kinase (contraction) and adaptor functions (structural integrity) of ILK in the vertebrate heart. Downregulation of the protein results in loss of phosphorylation of the putative substrate(s) and the biological response This has been shown extensively through small interfering RNA (siRNA)-mediated knockdown of ILK protein and gene ablation (reviewed by McDonald et al. (2008a) ). For example, ablation of ILK was associated with loss of Akt phosphorylation on Ser-473 White et al., 2006; Wang et al., 2008; Pereira et al., 2009) . On the other hand, ILK depletion in vascular smooth-muscle cells was actually associated with hyper-phosphorylation of MLC-20 (Kogata et al., 2009; Montanez et al., 2009) , although this could be because of compensation by other kinases capable of phosphorylating MLC-20, such as Rho-associated kinase (Amano et al., 1996) or zipper-interacting protein kinase (Murata-Hori et al., 1999; Niiro and Ikebe, 2001) . Also, phosphorylation of Akt or GSK-3b was not altered in a variety of cell types following ILK deletion Sakai et al., 2003; Lorenz et al., 2007) .
Expression of a dominant-negative mutant prevents phosphorylation of the putative substrate(s) and the biological response Kinase-deficient, dominant-negative constructs (and small-molecule ILK inhibitors; see below) can block ILK signaling in various cell types, but most notably in cancer cells, inhibiting phosphorylation of the downstream kinases, Akt, p70S6K and GSK-3b, in cell cultures and in vivo in tumor xenograft models (Hannigan et al., 2005; McDonald et al., 2008a; Cabodi et al., 2010) . These results suggest that ILK is affecting cell survival and proliferation through its catalytic activity. However, the possibility that these mutations affect critical proteinprotein interactions still exists.
Knock-in of demonstrated kinase-dead mutants produces significant phenotypes in vivo, and shows loss of phosphorylation of the kinase substrates For ILK, neither did knock-in of S343A and E359K, putative kinase-dead mutants, result in deleterious developmental defects in the mouse or changes in the phosphorylation of Akt or GSK-3b, nor did knock-in of the constitutively active S343D (Lange et al., 2009 ). However, knock-in of the K220M mutant, which has recently been shown to be significantly kinase-deficient (Maydan et al., 2010) , resulted in severe renal developmental and functional defects (Lange et al., 2009) . However, as discussed above, these defects were attributed to failure of this mutant to bind to a-parvin. As argued above, these effects could equally be because of loss of kinase activity and, therefore, further analysis of these mice is required.
The kinase activity is inhibited by a specific smallmolecule inhibitor with identical K i and K m values The in vitro kinase activity of purified ILK is sensitive to the QLT class of small-molecule ILK inhibitors, such as QLT0267 (Maydan et al., 2010) , which have been used to implicate ILK activity in numerous biological responses (see above). The selectivity of this small molecule for ILK relative to other kinases has been determined by analyzing its effects on 150 recombinant kinases (Younes et al., 2005; Troussard et al., 2006) . It should be noted that whereas most kinases are not affected by this molecule, the kinase Flt-3 is inhibited by QLT0267, with a K i that resembles that of ILK, and acute myelogenous leukemia cells expressing both ILK and active Flt-3 are sensitive to this inhibitor compared with normal bone marrow leukocytes (Muranyi et al., 2010) .
These inhibitors act in an ATP-competitive manner in vitro (Maydan et al., 2010) . Inhibition of ILK activity using small molecules (or siRNA) supports a role for ILK acting downstream from PI3K to mediate phosphorylation of key growth-regulatory molecules such as Akt and GSK-3b (Figure 1) , thereby affecting the processes of cell survival, proliferation and migration, especially in cancer cells and many common tumors in which ILK protein levels are elevated (McDonald et al., 2008a) . Interestingly, ILK, which binds directly to Rictor (McDonald et al., 2008b) , has also been shown to regulate the phosphorylation of Rictor on Thr-1135, a site linked to growth factor-and oncogene-mediated activation of mTORC2 (Boulbes et al., 2010) .
ILK expression is significantly elevated in many types of human cancers and in many cases its expression level predicts poor patient outcome. The roles of ILK in mammary differentiation and breast cancer have shed light on the context-dependent adaptor and signaling functions of ILK with respect to physiologic and pathologic conditions. In the mammary gland, ILK is an essential downstream effector of lactogenesis in vivo and the differentiation of mammary epithelial cells in 3D cell culture (Akhtar et al., 2009 ). Lack of ILKmediated phosphorylation of known targets (GSK-3b, Akt or ERKs) in vivo suggested a kinase-independent role of ILK in regulating lactogenesis. Conversely, ILK kinase activity seems to have an important role in the development and progression of cancer. Focal mammary tumors in MMTV-ILK-expressing mice show constitutive phosphorylation of GSK-3b, Akt and ERKs (White et al., 2001) , suggesting a catalytic activity of ILK in promoting tumor formation. Furthermore, ILK mediates the phosphorylation of Akt and cell survival in cancer cells, but not in untransformed epithelial cells or other normal cell types (Troussard et al., 2006) , likely because of an mTOR-independent interaction of ILK with Rictor, which results in elevated Akt phosphorylation (McDonald et al., 2008b) . Akt Ser-473 phosphorylation is sensitive to QLT0267 (and dominant-negative ILK) only in cancer cells, indicating increased cancer cell survival through acquisition of a dependence on ILK kinase activity. ILK-induced phosphorylation of GSK-3b on Ser-9 is associated with inhibition of GSK-3b activity and stabilization of bcatenin (Oloumi et al., 2006) . When co-expressed with Wnt1 in luminal epithelial cells, ILK cooperates to potentiate the induction of mammary tumors, involving increased phosphorylation of GSK-3b Ser-9 and nuclear translocation of b-catenin in the transformed luminal epithelial cells in vivo (Oloumi et al., 2010) . This result supports the phosphorylation of Ser-9 by ILK, as a GSK-3b peptide substrate containing Ser-9 is phosphorylated in vitro using near-homogeneous preparations of full-length recombinant ILK. ILK protein levels are elevated in the mammary tumors of mice expressing an MMTV-ErbB2 transgene. The onset of ErbB2-dependent tumors is markedly delayed when ILK is deleted in pre-malignant epithelial cells. Inhibition of ILK activity using a small-molecule inhibitor (or siRNA-mediated deletion) suppresses the invasive properties of ErbB2-expressing mammary epithelial cells in vitro, suggesting a role for ILK kinase activity in ErbB2-induced mammary tumor development and progression (Pontier et al., 2010) . Alternatively, a small-molecule ILK inhibitor and an ILK-specific siRNA show identical off-target profiles in the mammary epithelium. In PTEN-null prostate cancer cells, ILK activity is constitutively elevated, leading to constitutive phosphorylation of Akt on Ser-473, and inhibition of ILK activity using kinase domain, dominant-negative mutants or a small-molecule ILK inhibitor, induces cell-cycle arrest and apoptosis in these cells (Persad et al., 2000) . Furthermore, ILK stimulates hypoxia-inducible factor-1a expression in PTEN-null prostate cancer cells in an Akt/mTOR-dependent manner, leading to the expression and secretion of elevated levels of vascular endothelial growth factor (Tan et al., 2004) . In endothelial cells, vascular endothelial growth factor stimulates ILK activity, which regulates angiogenesis, and inhibition of ILK activity with small-molecule inhibitors in PTEN-null prostate cancer xenografts inhibits tumor angiogenesis and tumor growth in vivo (Tan et al., 2004) . The involvement of ILK kinase activity in tumor growth and metastasis has been further exemplified through the significant suppressive effects of small-molecule ILK kinase activity inhibitors on tumor growth in the thyroid (Younes et al., 2005) , prostate (Tan et al., 2004) , pancreas (Yau et al., 2005) and lung (Liu et al., 2006) , and in acute myelogenous leukemia (Muranyi et al., 2010) in vivo.
The kinase function of ILK is also likely to be important in the context of its localization and role in centrosomes, where ILK has been shown to regulate centrosome clustering in cancer cells (Fielding et al., 2011) . Both siRNA-mediated ILK knockdown and inhibition of ILK kinase activity with QLT0267 resulted in centrosome de-clustering, by inhibiting TACC3 phosphorylation, in breast and prostate cancer cells harboring supernumerary centrosomes, and this resulted in the inhibition of clonogenic potential and mitotic arrest, specifically in cancer cells relative to mammary and prostatic epithelial cells harboring two centrosomes (Fielding et al., 2011) . Taken together, these new insights further support a role for ILK kinase activity and signaling in cancer, and suggest that targeting ILK kinase activity may provide a novel cancer cell-specific therapeutic strategy (Cabodi et al., 2010) .
The 3D structure of the kinase-inhibitor complex shows the mechanism of inhibition of kinase activity The 3D structure of a complex of ILK with a smallmolecule inhibitor such as QLT0267 has not yet been determined, but should be a priority for the future. Part of the problem lies in the difficulty of expressing soluble, full-length ILK (see below).
Additional approaches that could resolve the controversy
Biochemical studies have clearly shown that ILK possesses robust intrinsic protein serine/threonine kinase activity in vitro. We have also highlighted key genetic studies supporting the conclusion that ILK is a multifunctional protein, playing diverse and complex roles in vertebrate physiology and pathology. The theme of contextual regulation of ILK activity emerges from these studies, and it is possible that the relative contributions of its kinase and adaptor functions depend on tissue-and stage-specific developmental requirements, as well as consideration of normal versus pathological conditions. In addition, distinct subcellular localizations likely impose functional constraints on ILK, reflecting distinct protein interactions and perhaps also the physicochemical microenvironment.
Determination of the mechanism and regulation of enzyme catalysis by the ILK kinase domain must await the solution of the crystal structure of uncomplexed, full-length ILK, and various kinase domain mutants. In addition, solution of the crystal structure in the presence of ATP-competitive small-molecule inhibitors, such as QLT0267, should provide important information about the mechanism of catalysis. Progress toward obtaining the 3D structure of full-length ILK has been impeded to date, due to poor solubility and stability of ILK expressed in E. coli, necessitating expression of the catalytic domain of ILK bound to other proteins. With the successful expression of active, full-length ILK, as well as inactive ILK mutants, in insect and mammalian cells (Maydan et al., 2010) , it should now be possible to solve this structure and gain insights into the mechanism of action of this fascinating kinase domain. It will be interesting to determine which amino acids can substitute for the missing DFG and HRD motifs, and these studies will further our understanding of the versatility of kinase domains, as discussed recently for other atypical kinases (Taylor and Kornev, 2010) .
Conclusions
The principal argument that ILK is a pseudokinase is based on the primary structure of its atypical protein kinase domain, which lacks certain amino-acid residues thought to be essential for phosphotransferase activity (Boudeau et al., 2006) . However, similar deficiencies in canonical residues are present in the catalytic domains of other kinases such as CASK, haspin, Wnk1, VRK3 and ErbB3, all thought to be pseudokinases at one time but recently shown to possess protein kinase activity (Taylor and Kornev, 2010) . The crystal structure of the kinase domain in complex with the C-terminal CH domain of a-parvin was interpreted as supporting ILK being a pseudokinase. However, this structure may be locked into an inactive conformation as binding of a-parvin to full-length ILK inhibits its kinase activity and, therefore, it is unclear how this structure leads to the conclusion that ILK is a pseudokinase. Interestingly, ErbB3 kinase activity requires what was thought to be an inactive conformation in the kinase domain, thus precluding the dogmatic notions of active and inactive catalytic structures (Taylor and Kornev, 2010) . These studies highlight the ability of the kinase fold to adapt in unique ways to promote the phosphorylation of one or more substrates.
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